Inhibitors of cyclin-dependent kinases as new class of drugs in oncology. Achievements and development prospects in treatment of ER+ /HER 2- breast cancer

Abstract

The review is devoted to a new class of drugs - inhibitors of cy-clin-dependent kinases. The discovery of the genetic and molecular mechanisms of cell cycle regulation, and as a result, the emergence of CDK4 / 6 inhibitors was a breakthrough in the treatment of ER+ HER2- metastatic breast cancer and changed the paradigm of hormone therapy in this group of patients. We consider the current role of CDK4 / 6 inhibitors in treating patients with hormone-sensitive breast cancer, as well as the prospects for the future use of this class of drugs. The article presents the results of the main registration studies of the FDA-approved inhibitors of CDK4 / 6: palbocyclyb, ribocyclyb, abemocyclib; a comparative analysis of their efficacy and toxicity profile was carried out.